Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE5.7800
- TODAY'S CHANGE (%)-0.1300 (-2.1997%)
- Bid / Lots5.7500/ 2
- Ask / Lots6.1500/ 1
- Open / Previous Close5.9900 / 5.9100
- Day Range
- 52 Week Range
- Volume327,090
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 3905 | 5.99 |
| 09:34 ET | 100 | 5.95 |
| 09:36 ET | 300 | 5.91 |
| 09:38 ET | 5267 | 5.92 |
| 09:41 ET | 200 | 5.9417 |
| 09:48 ET | 1392 | 5.91 |
| 09:54 ET | 200 | 5.94 |
| 09:56 ET | 2290 | 5.93 |
| 09:57 ET | 903 | 5.87 |
| 09:59 ET | 9197 | 5.845 |
| 10:01 ET | 600 | 5.86 |
| 10:03 ET | 1629 | 5.865 |
| 10:06 ET | 111 | 5.89 |
| 10:08 ET | 737 | 5.89 |
| 10:10 ET | 800 | 5.85 |
| 10:14 ET | 3130 | 5.8698 |
| 10:15 ET | 3821 | 5.8006 |
| 10:17 ET | 2426 | 5.8 |
| 10:19 ET | 623 | 5.79 |
| 10:21 ET | 5100 | 5.751 |
| 10:24 ET | 648 | 5.76 |
| 10:26 ET | 3682 | 5.75 |
| 10:28 ET | 1605 | 5.79 |
| 10:30 ET | 3105 | 5.7884 |
| 10:32 ET | 200 | 5.76 |
| 10:33 ET | 4548 | 5.79 |
| 10:35 ET | 4891 | 5.77 |
| 10:37 ET | 100 | 5.77 |
| 10:39 ET | 200 | 5.75 |
| 10:42 ET | 663 | 5.76 |
| 10:44 ET | 100 | 5.73 |
| 10:46 ET | 451 | 5.765 |
| 10:48 ET | 9771 | 5.8 |
| 10:50 ET | 230 | 5.8 |
| 10:51 ET | 1500 | 5.8 |
| 10:53 ET | 400 | 5.78 |
| 10:55 ET | 100 | 5.78 |
| 10:57 ET | 224 | 5.78 |
| 11:00 ET | 638 | 5.76 |
| 11:02 ET | 603 | 5.78 |
| 11:04 ET | 400 | 5.81 |
| 11:06 ET | 2150 | 5.8099 |
| 11:09 ET | 392 | 5.828 |
| 11:11 ET | 555 | 5.8274 |
| 11:13 ET | 345 | 5.81 |
| 11:18 ET | 100 | 5.835 |
| 11:22 ET | 100 | 5.85 |
| 11:24 ET | 100 | 5.84 |
| 11:26 ET | 1300 | 5.85 |
| 11:27 ET | 250 | 5.885 |
| 11:31 ET | 200 | 5.88 |
| 11:33 ET | 100 | 5.87 |
| 11:36 ET | 100 | 5.88 |
| 11:38 ET | 2033 | 5.89 |
| 11:40 ET | 297 | 5.88 |
| 11:42 ET | 400 | 5.9 |
| 11:44 ET | 100 | 5.88 |
| 11:45 ET | 600 | 5.89 |
| 11:47 ET | 200 | 5.89 |
| 11:49 ET | 200 | 5.89 |
| 11:51 ET | 348 | 5.87 |
| 11:56 ET | 300 | 5.87 |
| 11:58 ET | 100 | 5.87 |
| 12:00 ET | 200 | 5.85 |
| 12:02 ET | 200 | 5.84 |
| 12:03 ET | 1100 | 5.83 |
| 12:07 ET | 100 | 5.84 |
| 12:09 ET | 100 | 5.82 |
| 12:12 ET | 4000 | 5.82 |
| 12:14 ET | 100 | 5.83 |
| 12:18 ET | 7534 | 5.8001 |
| 12:21 ET | 202 | 5.802 |
| 12:23 ET | 489 | 5.8 |
| 12:25 ET | 1276 | 5.8 |
| 12:32 ET | 2551 | 5.78 |
| 12:36 ET | 1920 | 5.762 |
| 12:38 ET | 300 | 5.78 |
| 12:39 ET | 400 | 5.78 |
| 12:41 ET | 100 | 5.78 |
| 12:43 ET | 500 | 5.7614 |
| 12:45 ET | 12780 | 5.7602 |
| 12:48 ET | 200 | 5.78 |
| 12:50 ET | 600 | 5.77 |
| 12:52 ET | 2178 | 5.75 |
| 12:54 ET | 1400 | 5.75 |
| 12:56 ET | 627 | 5.76 |
| 12:57 ET | 520 | 5.77 |
| 12:59 ET | 1135 | 5.78 |
| 01:01 ET | 220 | 5.77 |
| 01:03 ET | 5574 | 5.75 |
| 01:06 ET | 742 | 5.75 |
| 01:08 ET | 100 | 5.76 |
| 01:10 ET | 6369 | 5.73 |
| 01:12 ET | 420 | 5.72 |
| 01:14 ET | 7088 | 5.7 |
| 01:15 ET | 300 | 5.71 |
| 01:17 ET | 100 | 5.71 |
| 01:21 ET | 481 | 5.72 |
| 01:24 ET | 7143 | 5.73 |
| 01:26 ET | 5800 | 5.76 |
| 01:32 ET | 200 | 5.74 |
| 01:35 ET | 100 | 5.72 |
| 01:44 ET | 100 | 5.72 |
| 01:46 ET | 200 | 5.71 |
| 01:50 ET | 1161 | 5.73 |
| 01:51 ET | 300 | 5.73 |
| 02:02 ET | 1529 | 5.75 |
| 02:06 ET | 200 | 5.77 |
| 02:08 ET | 308 | 5.76 |
| 02:09 ET | 1429 | 5.755 |
| 02:15 ET | 400 | 5.74 |
| 02:20 ET | 100 | 5.74 |
| 02:22 ET | 1700 | 5.7485 |
| 02:24 ET | 249 | 5.75 |
| 02:26 ET | 2363 | 5.745 |
| 02:27 ET | 1000 | 5.7426 |
| 02:29 ET | 901 | 5.755 |
| 02:31 ET | 994 | 5.7486 |
| 02:40 ET | 200 | 5.75 |
| 02:45 ET | 500 | 5.765 |
| 02:51 ET | 200 | 5.75 |
| 02:54 ET | 1000 | 5.7465 |
| 02:58 ET | 433 | 5.7598 |
| 03:02 ET | 100 | 5.7421 |
| 03:03 ET | 985 | 5.7679 |
| 03:05 ET | 3490 | 5.78 |
| 03:07 ET | 100 | 5.77 |
| 03:09 ET | 200 | 5.76 |
| 03:18 ET | 100 | 5.77 |
| 03:20 ET | 454 | 5.76 |
| 03:23 ET | 200 | 5.75 |
| 03:25 ET | 880 | 5.735 |
| 03:27 ET | 1151 | 5.75 |
| 03:30 ET | 4087 | 5.76 |
| 03:32 ET | 100 | 5.78 |
| 03:34 ET | 748 | 5.77 |
| 03:38 ET | 200 | 5.78 |
| 03:39 ET | 1679 | 5.8 |
| 03:41 ET | 454 | 5.8 |
| 03:43 ET | 566 | 5.78 |
| 03:45 ET | 2940 | 5.79 |
| 03:48 ET | 200 | 5.789 |
| 03:52 ET | 3177 | 5.7635 |
| 03:54 ET | 2971 | 5.8 |
| 03:56 ET | 1396 | 5.79 |
| 03:57 ET | 1699 | 5.79 |
| 03:59 ET | 43185 | 5.78 |
Sep 5, 2024
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26(th) Annual Global Investment Conference, from 7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 351.2M | -9.1x | --- |
Jasper Therapeutics Inc | 346.5M | -4.5x | --- |
Monte Rosa Therapeutics Inc | 344.9M | -2.6x | --- |
Corvus Pharmaceuticals Inc | 361.5M | -12.3x | --- |
Nautilus Biotechnology Inc | 371.2M | -5.2x | --- |
Atea Pharmaceuticals Inc | 328.4M | -1.9x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Principal Financial Officer and Principal Accounting Officer
- Michael Alfieri
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $351.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.43 |
EPS | $-0.64 |
Book Value | $2.02 |
P/E Ratio | -9.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
